Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 134 | 31 | 98 |
| Samples | 124 | 31 | 89 |
| Peptides | 102 | 19 | 83 |
Function
TAF9B · TATA-box binding protein associated factor 9b
Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes a protein that is similar to one of the small subunits of TFIID, TBP-associated factor 9, and is also a subunit of TFIID. TAF9 and TAF9b share some functions but also have distinct roles in the transcriptional regulatory process. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000341864 | Q9HBM6 | 134 | 102 |
Gene Properties
Recurrent Mutations
All 102 amino-acid changes on canonical ENST00000341864 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TAF9B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TAF9B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 1/42 2% | 17/612 3% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 6/1390 0% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Colorectal Carcinoma | 2/143 1% | 19/3239 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 2/810 0% |
| Other Sarcomas | 3/69 4% | 1/699 0% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Melanoma | 3/210 1% | 6/1899 0% |
| Gastric Carcinoma | 1/74 1% | 7/1809 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Other Solid Cancers | 2/94 2% | 3/1515 0% |
| Hepatocellular Carcinoma | 0/46 0% | 6/2210 0% |
| Kidney Carcinoma | 1/85 1% | 4/1862 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Non-Cancerous | 1/104 1% | 0/830 0% |
| Ovarian Carcinoma | 0/109 0% | 1/998 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 2/2550 0% |
| Breast Carcinoma | 0/144 0% | 2/3264 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 0/2534 0% |
| Other Blood Cancers | 0/61 0% | 1/2725 0% |
Mutation Distribution
Where TAF9B is mutated · all tissues, split by cell line vs tissue
How many mutations in TAF9B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 134 mutations in TAF9B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|